{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:20:16Z","timestamp":1789676416144,"version":"4.0.1"},"reference-count":198,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Immunotherapies provide a potential treatment option for currently incurable bone metastases. Bone marrow is an important secondary lymphoid organ with a unique immune contexture. Even at non-disease state immune cells and bone cells interact with each other, bone cells supporting the development of immune cells and immune cells regulating bone turnover. In cancer, tumor cells interfere with this homeostatic process starting from formation of pre-metastatic niche and later supporting growth of bone metastases. In this review, we introduce a novel concept osteoimmuno-oncology (OIO), which refers to interactions between bone, immune and tumor cells in bone metastatic microenvironment. We also discuss therapeutic opportunities of targeting immune cells in bone metastases, and associated efficacy and safety concerns.<\/jats:p>","DOI":"10.3390\/cells10061529","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T11:20:26Z","timestamp":1623928826000},"page":"1529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Osteoimmuno-Oncology: Therapeutic Opportunities for Targeting Immune Cells in Bone Metastasis"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6496-1845","authenticated-orcid":false,"given":"Tiina E.","family":"K\u00e4hk\u00f6nen","sequence":"first","affiliation":[{"name":"OncoBone Ltd., 90810 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi M.","family":"Halleen","sequence":"additional","affiliation":[{"name":"OncoBone Ltd., 90810 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Bernoulli","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine, University of Turku, 20500 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2018.02.005","article-title":"Immuno-oncology-101: Overview of major concepts and translational perspectives","volume":"52","author":"Allard","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdx755","article-title":"Comprehensive analysis of the clinical immuno-oncology landscape","volume":"29","author":"Tang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-030-24100-1_8","article-title":"Immuno-Oncology in the Era of Personalized Medicine","volume":"1168","author":"Gwin","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold Tumors: A Therapeutic Challenge for Immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/ijc.32889","article-title":"Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination","volume":"147","author":"Dardenne","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Cesano, A., and Warren, S. (2018). Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. Biomedicines, 6.","DOI":"10.3390\/biomedicines6010014"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-Oncology: Emerging Targets and Combination Therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1586\/14737140.2015.1059279","article-title":"The importance of the tumor microenvironment in the therapeutic management of cancer","volume":"15","author":"Pottier","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zheng, J., and Gao, P. (2019). Toward Normalization of the Tumor Microenvironment for Cancer Therapy. Integr. Cancer Ther., 18.","DOI":"10.1177\/1534735419862352"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cels.2019.07.003","article-title":"Kshitiz Systems Biology of Cancer Metastasis","volume":"9","author":"Suhail","year":"2019","journal-title":"Cell Syst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT Transition States during Tumor Progression and Metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12272-018-01108-7","article-title":"Therapeutic implications of cancer epithelial-mesenchymal transition (EMT)","volume":"42","author":"Cho","year":"2019","journal-title":"Arch. Pharmacal Res."},{"key":"ref_16","first-page":"762","article-title":"Intravasation as a Key Step in Cancer Metastasis","volume":"84","author":"Zavyalova","year":"2019","journal-title":"Biochemistry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10585-007-9098-2","article-title":"Stepping out of the flow: Capillary extravasation in cancer metastasis","volume":"25","author":"Miles","year":"2007","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2015.11.017","article-title":"Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer","volume":"99","author":"Futakuchi","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10555-015-9586-9","article-title":"The challenge of targeting metastasis","volume":"34","author":"Fidler","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/01.ju.0000051580.89109.4b","article-title":"Metastasis Suppression: The Evolving Role of Metastasis Suppressor Genes for Regulating Cancer Cell Growth at the Secondary Site","volume":"169","author":"Kauffman","year":"2003","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2018.01.003","article-title":"Breast cancer bone metastases: Pathogenesis and therapeutic targets","volume":"96","author":"Brook","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10555-017-9719-4","article-title":"Current perspectives on bone metastases in castrate-resistant prostate cancer","volume":"37","author":"Logothetis","year":"2018","journal-title":"Cancer Metastasis Rev."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hernandez, R.K., Wade, S.W., Reich, A., Pirolli, M., Liede, A., and Lyman, G.H. (2018). Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer, 18.","DOI":"10.1186\/s12885-017-3922-0"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12094-014-1247-x","article-title":"Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics","volume":"17","author":"Fang","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/cmi.2011.47","article-title":"Bone marrow and the control of immunity","volume":"9","author":"Zhao","year":"2011","journal-title":"Cell. Mol. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2017.213","article-title":"Updating osteoimmunology: Regulation of bone cells by innate and adaptive immunity","volume":"14","author":"Walsh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.critrevonc.2017.05.004","article-title":"Overcoming immunosuppression in bone metastases","volume":"117","author":"Reinstein","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1172\/JCI60630","article-title":"Extrathymic development of murine T cells after bone marrow transplantation","volume":"122","author":"Holland","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2006-05-021089","article-title":"Naive recirculating B cells mature simultaneously in the spleen and bone marrow","volume":"109","author":"Cariappa","year":"2006","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1247\/csf.17018","article-title":"Bone Marrow Endothelial Cells Induce Immature and Mature B Cell Egress in Response to Erythropoietin","volume":"42","author":"Ito","year":"2017","journal-title":"Cell Struct. Funct."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.celrep.2017.01.067","article-title":"T Regulatory Cells Support Plasma Cell Populations in the Bone Marrow","volume":"18","author":"Zaretsky","year":"2017","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/icb.2017.68","article-title":"Interleukin-7 in the transition of bone marrow progenitors to the thymus","volume":"95","author":"Plumb","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1084\/jem.20180778","article-title":"Cell circuits between B cell progenitors and IL-7+ mesenchymal progenitor cells control B cell development","volume":"215","author":"Fistonich","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/eji.201646307","article-title":"TSLP or IL-7 provide an IL-7R\u03b1 signal that is critical for human B lymphopoiesis","volume":"46","author":"Milford","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.1318281111","article-title":"Characterization of the IL-15 niche in primary and secondary lymphoid organs in vivo","volume":"111","author":"Cui","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/eji.201142019","article-title":"IL-15 inhibits IL-7R\u03b1 expression by memory-phenotype CD8+T cells in the bone marrow","volume":"42","author":"Quinci","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4049\/jimmunol.177.1.100","article-title":"Differential Effects of IL-15 and IL-21 in Myeloid (CD11b+) and Lymphoid (CD11b\u2212) Bone Marrow Cells","volume":"177","author":"Pelletier","year":"2006","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3389\/fimmu.2019.02182","article-title":"Chemokines in Physiological and Pathological Bone Remodeling","volume":"10","author":"Brylka","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.4049\/jimmunol.1800529","article-title":"Active mTORC2 Signaling in Naive T Cells Suppresses Bone Marrow Homing by Inhibiting CXCR4 Expression","volume":"201","author":"Arojo","year":"2018","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3389\/fimmu.2019.01262","article-title":"Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X","volume":"10","author":"Levy","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4049\/jimmunol.182.1.604","article-title":"Crosstalk between CXCR4\/Stromal Derived Factor-1 and VLA-4\/VCAM-1 Pathways Regulates Neutrophil Retention in the Bone Marrow","volume":"182","author":"Petty","year":"2009","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.molimm.2006.08.021","article-title":"VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF","volume":"44","author":"Schaumann","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"a031245","DOI":"10.1101\/cshperspect.a031245","article-title":"Osteoimmunology","volume":"9","author":"Okamoto","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-019-0178-8","article-title":"Osteoimmunology: Evolving concepts in bone\u2013immune interactions in health and disease","volume":"19","author":"Tsukasaki","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Su, P., Tian, Y., Yang, C., Ma, X., Wang, X., Pei, J., and Qian, A. (2018). Mesenchymal Stem Cell Migration during Bone Formation and Bone Diseases Therapy. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082343"},{"key":"ref_47","first-page":"327","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nat. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-5793(96)01495-0","article-title":"Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis","volume":"402","author":"Feuerbach","year":"1997","journal-title":"FEBS Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0014-5793(03)00182-0","article-title":"Crosslinking of CD44 on human osteoblastic cells upregulates ICAM-1 and VCAM-1","volume":"539","author":"Fujii","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.abb.2014.06.032","article-title":"Roles of osteoclasts in the control of medullary hematopoietic niches","volume":"561","author":"Rouleau","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5582\/bst.2015.01073","article-title":"DHEA promotes osteoblast differentiation by regulating the expression of osteoblast-related genes and Foxp3(+) regulatory T cells","volume":"9","author":"Qiu","year":"2015","journal-title":"Biosci. Trends"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.bbmt.2015.05.005","article-title":"Granulocyte Colony-Stimulating Factor Induces Osteoblast Inhibition by B Lymphocytes and Osteoclast Activation by T Lymphocytes during Hematopoietic Stem\/Progenitor Cell Mobilization","volume":"21","author":"Li","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00223-013-9753-3","article-title":"Interactions Between B Lymphocytes and the Osteoblast Lineage in Bone Marrow","volume":"93","author":"Panaroni","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/jbmr.1608","article-title":"Absence of sclerostin adversely affects B-cell survival","volume":"27","author":"Cain","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/cr.2011.21","article-title":"Osteoclast activity modulates B-cell development in the bone marrow","volume":"21","author":"Mansour","year":"2011","journal-title":"Cell Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/jbmr.2581","article-title":"PTH Signaling in Osteoprogenitors Is Essential for B-Lymphocyte Differentiation and Mobilization","volume":"30","author":"Panaroni","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-\u03b3","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jbmr.2096","article-title":"Physiological Functions of Osteoblast Lineage and T Cell-Derived RANKL in Bone Homeostasis","volume":"29","author":"Fumoto","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_60","first-page":"299","article-title":"Bu-Shen-Ning-Xin decoction suppresses osteoclastogenesis by modulating RANKL\/OPG imbalance in the CD4+ T lymphocytes of ovariectomized mice","volume":"42","author":"Zhang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.4049\/jimmunol.167.5.2625","article-title":"Connection Between B Lymphocyte and Osteoclast Differentiation Pathways","volume":"167","author":"Manabe","year":"2001","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/0022034518759302","article-title":"RANKL Triggers Treg-Mediated Immunoregulation in Inflammatory Osteolysis","volume":"97","author":"Francisconi","year":"2018","journal-title":"J. Dent. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.12659\/MSM.912119","article-title":"Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-\u03baB Ligand (RANKL)","volume":"25","author":"Tilkeridis","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.0105-2896.2005.00328.x","article-title":"B cells and osteoblast and osteoclast development","volume":"208","author":"Horowitz","year":"2005","journal-title":"Immunol. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"24838","DOI":"10.1074\/jbc.M116.742452","article-title":"RANKL (Receptor Activator of NF\u03baB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice","volume":"291","author":"Fujiwara","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5483\/BMBRep.2008.41.7.495","article-title":"Osteoimmunology: Cytokines and the skeletal system","volume":"41","author":"Lee","year":"2008","journal-title":"BMB Rep."},{"key":"ref_67","first-page":"1","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molimm.2017.11.023","article-title":"Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis","volume":"110","author":"Owen","year":"2019","journal-title":"Mol. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1574892812666170606123113","article-title":"Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis","volume":"12","author":"Luo","year":"2017","journal-title":"Recent Pat. Anti-Cancer Drug Discov."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/01.bor.0000231909.35043.da","article-title":"New insights into the role of T cells in the vicious cycle of bone metastases","volume":"18","author":"Fournier","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.7314\/APJCP.2014.15.13.5181","article-title":"Tumor-derived transforming growth factor-\u03b2 is critical for tumor progression and evasion from immune surveillance","volume":"15","author":"Li","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_73","first-page":"143526","article-title":"The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors","volume":"2015","author":"Roato","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1084\/jem.20020141","article-title":"Identification of a Mutated Fibronectin As a Tumor Antigen Recognized by CD4+T Cells: Its Role in Extracellular Matrix Formation and Tumor Metastasis","volume":"195","author":"Wang","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4049\/jimmunol.180.1.130","article-title":"Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases","volume":"180","author":"Lengagne","year":"2007","journal-title":"J. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/pros.23808","article-title":"PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells","volume":"79","author":"Vidotto","year":"2019","journal-title":"Prostate"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Xiang, L., and Gilkes, D.M. (2019). The Contribution of the Immune System in Bone Metastasis Pathogenesis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040999"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.ygyno.2009.11.020","article-title":"Ovarian cancer tumor infiltrating T-regulatory (Treg) cells are associated with a metastatic phenotype","volume":"116","author":"Barnett","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Karavitis, J., Hix, L.M., Shi, Y.H., Schultz, R.F., Khazaie, K., and Zhang, M. (2012). Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0046342"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hix, L.M., Shi, Y.H., Brutkiewicz, R.R., Stein, P.L., Wang, C.-R., and Zhang, M. (2011). CD1d-Expressing Breast Cancer Cells Modulate NKT Cell-Mediated Antitumor Immunity in a Murine Model of Breast Cancer Metastasis. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020702"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1172\/JCI69369","article-title":"Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis","volume":"123","author":"Liu","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-17-0341","article-title":"Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis","volume":"5","author":"Mittal","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semcancer.2018.08.001","article-title":"NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis","volume":"53","author":"Jewett","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-15-0065","article-title":"Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer","volume":"3","author":"Rautela","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fimmu.2019.00172","article-title":"MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation","volume":"10","author":"Wang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_87","first-page":"E2376","article-title":"NK cells require IL-28R for optimal in vivo activity","volume":"112","author":"Young","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/A:1022621622063","article-title":"A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice","volume":"20","author":"Zhang","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"12258","DOI":"10.1038\/ncomms12258","article-title":"Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models","volume":"7","author":"Bottos","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Biswas, S., Nyman, J.S., Alvarez, J., Chakrabarti, A., Ayres, A., Sterling, J., Edwards, J., Rana, T., Johnson, R., and Perrien, D.S. (2011). Anti-Transforming Growth Factor \u00df Antibody Treatment Rescues Bone Loss and Prevents Breast Cancer Metastasis to Bone. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027090"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1673-8527(09)60061-8","article-title":"Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis","volume":"37","author":"Ye","year":"2010","journal-title":"J. Genet. Genom."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00262-019-02472-z","article-title":"Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer","volume":"69","author":"Bergenfelz","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13058-019-1189-x","article-title":"Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs","volume":"21","author":"Bosiljcic","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"36663","DOI":"10.1038\/srep36663","article-title":"Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis","volume":"6","author":"Wei","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1158\/0008-5472.CAN-13-3171","article-title":"BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity","volume":"74","author":"Cao","year":"2014","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1021\/jm101577z","article-title":"Conjugate (MTC-220) of Muramyl Dipeptide Analogue and Paclitaxel Prevents Both Tumor Growth and Metastasis in Mice","volume":"54","author":"Ma","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.intimp.2014.06.006","article-title":"Dexamethasone inhibits in vivo tumor growth by the alteration of bone marrow CD11b+ myeloid cells","volume":"21","author":"Moon","year":"2014","journal-title":"Int. Immunopharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-13-0305","article-title":"Myeloid-Derived Suppressor Cells as Osteoclast Progenitors: A Novel Target for Controlling Osteolytic Bone Metastasis","volume":"73","author":"Sawant","year":"2013","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-17-1004","article-title":"BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer","volume":"23","author":"Rubio","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-017-00523-6","article-title":"Caspase-1 cleaves PPAR\u03b3 for potentiating the pro-tumor action of TAMs","volume":"8","author":"Niu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-10-2047","article-title":"Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents","volume":"17","author":"Buddingh","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3892\/ijo.2014.2293","article-title":"Involvement of CXCL14 in osteolytic bone metastasis from lung cancer","volume":"44","author":"Takiguchi","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1349-7006.2008.00880.x","article-title":"Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes\/macrophages","volume":"99","author":"Hiraoka","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neo.2018.11.003","article-title":"Trabectedin Reduces Skeletal Prostate Cancer Tumor Size in Association with Effects on M2 Macrophages and Efferocytosis","volume":"21","author":"Jones","year":"2019","journal-title":"Neoplasia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"106012","DOI":"10.1016\/j.intimp.2019.106012","article-title":"Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages","volume":"78","author":"Jing","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cyto.2018.03.032","article-title":"M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis","volume":"118","author":"Shrivastava","year":"2019","journal-title":"Cytokine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/path.4718","article-title":"CD169+macrophages mediate pathological formation of woven bone in skeletal lesions of prostate cancer","volume":"239","author":"Wu","year":"2016","journal-title":"J. Pathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00002371-200311000-00002","article-title":"NK Cells Mediate Flt3 Ligand-Induced Protection of Dendritic Cell Precursors In Vivo from the Inhibition by Prostate Carcinoma in the Murine Bone Marrow Metastasis Model","volume":"26","author":"Tourkova","year":"2003","journal-title":"J. Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-9966-31-3","article-title":"Inhibition of dendritic cell migration by transforming growth factor-\u03b21 increases tumor-draining lymph node metastasis","volume":"31","author":"Imai","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3892\/or_00001028","article-title":"Transforming growth factor \u03b2 signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity","volume":"24","author":"Tanaka","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11845-014-1145-9","article-title":"Concurrent dendritic cell vaccine and strontium-89 radiation therapy in the management of multiple bone metastases","volume":"184","author":"Liu","year":"2014","journal-title":"Ir. J. Med Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3892\/or.2013.2224","article-title":"Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma","volume":"29","author":"Kawano","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cytogfr.2016.03.012","article-title":"Chemokine regulation of neutrophil function in tumors","volume":"30","author":"Bonavita","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41467-018-03080-8","article-title":"ACKR2 in hematopoietic precursors as a checkpoint of neutrophil release and anti-metastatic activity","volume":"9","author":"Massara","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"112132","DOI":"10.18632\/oncotarget.22792","article-title":"The regulation of pre-metastatic niche formation by neutrophils","volume":"8","author":"Jablonska","year":"2017","journal-title":"Oncotarget"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/s41590-018-0229-5","article-title":"Unique pattern of neutrophil migration and function during tumor progression","volume":"19","author":"Patel","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-020-02527-6","article-title":"Neutrophils are mediators of metastatic prostate cancer progression in bone","volume":"69","author":"Keeley","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-017-0552-6","article-title":"Cancer immunotherapy beyond immune checkpoint inhibitors","volume":"11","author":"Soyano","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-013-9452-6","article-title":"Adoptive immunotherapy of metastatic breast cancer: Present and future","volume":"33","author":"Stefanovic","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Monteiro, A.C., Leal, A.C., Gon\u00e7alves-Silva, T., Mercadante, A.C.T., Kestelman, F., Chaves, S., Azevedo, R.B., Monteiro, J.P., and Bonomo, A. (2013). T Cells Induce Pre-Metastatic Osteolytic Disease and Help Bone Metastases Establishment in a Mouse Model of Metastatic Breast Cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068171"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1054\/bjoc.2001.2136","article-title":"A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2","volume":"85","author":"Correale","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00262-013-1414-x","article-title":"Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: Follow-up analysis of a clinical pilot trial","volume":"62","author":"Domschke","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Juric, V., O\u2019Sullivan, C., Stefanutti, E., Kovalenko, M., Greenstein, A., Barry-Hamilton, V., Mikaelian, I., Degenhardt, J., Yue, P., and Smith, V. (2018). MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207255"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ijc.24461","article-title":"A high proportion of bone marrow T cells with regulatory phenotype (CD4+CD25hiFoxP3+) in Ewing sarcoma patients is associated with metastatic disease","volume":"125","author":"Brinkrolf","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fendo.2019.00145","article-title":"The Uncovered Role of Immune Cells and NK Cells in the Regulation of Bone Metastasis","volume":"10","author":"Roato","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.molimm.2008.06.016","article-title":"NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways","volume":"45","author":"Verhoeven","year":"2008","journal-title":"Mol. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e1593809","DOI":"10.1080\/2162402X.2019.1593809","article-title":"The role of NK cells and CD39 in the immunological control of tumor metastases","volume":"8","author":"Zhang","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_128","first-page":"511","article-title":"Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice","volume":"25","author":"Zhao","year":"2017","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.11586","article-title":"Parathyroid hormone-related protein (PTHrP) is responsible for production of bone metastasis, but not visceral metastasis, by human small cell lung cancer SBC-5 cells in natural killer cell-depleted SCID mice","volume":"108","author":"Miki","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1158\/1078-0432.CCR-07-1221","article-title":"Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell\u2013Depleted SCID Mice","volume":"14","author":"Ogino","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_131","first-page":"581","article-title":"A Bone Metastasis Model With Osteolytic and Osteoblastic Properties of Human Lung Cancer ACC-LC-319\/bone2 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice","volume":"17","author":"Otsuka","year":"2009","journal-title":"Oncol. Res. Featur. Preclin. Clin. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.7150\/thno.26888","article-title":"Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages","volume":"8","author":"Arlauckas","year":"2018","journal-title":"Theranostics"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.4049\/jimmunol.1103553","article-title":"Tumor-Expressed Inducible Nitric Oxide Synthase Controls Induction of Functional Myeloid-Derived Suppressor Cells through Modulation of Vascular Endothelial Growth Factor Release","volume":"188","author":"Jayaraman","year":"2012","journal-title":"J. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.redox.2015.09.012","article-title":"The Oncogenic Properties Of The Redox Inflammatory Protein Inducible Nitric Oxide Synthase In ER(-) Breast Cancer","volume":"5","author":"Wink","year":"2015","journal-title":"Redox Biol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","article-title":"Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor","volume":"117","author":"Li","year":"2020","journal-title":"Mol. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.2147\/OTT.S200643","article-title":"CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases","volume":"12","author":"Zhang","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.4161\/onci.21990","article-title":"Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction","volume":"1","author":"Danilin","year":"2012","journal-title":"OncoImmunology"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Law, A.M.K., Valdes-Mora, F., and Gallego-Ortega, D. (2020). Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer. Cells, 9.","DOI":"10.3390\/cells9030561"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbo.2016.03.004","article-title":"The role of tumour-associated macrophages in bone metastasis","volume":"5","author":"Sousa","year":"2016","journal-title":"J. Bone Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","article-title":"Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment","volume":"11","author":"Wu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1158\/1078-0432.CCR-18-0125","article-title":"Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion","volume":"24","author":"Cho","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Mendoza-Reinoso, V., McCauley, L.K., and Fournier, P.G. (2020). Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 12.","DOI":"10.3390\/cancers12041014"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/bjc.2017.451","article-title":"WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages","volume":"118","author":"Lee","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.7150\/thno.29617","article-title":"CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes\/macrophages","volume":"9","author":"Jiang","year":"2019","journal-title":"Theranostics"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4161\/mabs.25743","article-title":"A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells","volume":"5","author":"Haegel","year":"2013","journal-title":"mAbs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/emm.2004.55","article-title":"Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination","volume":"36","author":"Kim","year":"2004","journal-title":"Exp. Mol. Med."},{"key":"ref_148","first-page":"56","article-title":"Migration of human dendritic cells after injection in patients with metastatic malignancies","volume":"59","author":"Morse","year":"1999","journal-title":"Cancer Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"eaal5081","DOI":"10.1126\/science.aal5081","article-title":"Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhighneutrophils","volume":"358","author":"Engblom","year":"2017","journal-title":"Science"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3892\/ol.2011.304","article-title":"The neutrophil\/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis","volume":"2","author":"Wang","year":"2011","journal-title":"Oncol. Lett."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41416-018-0231-6","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with bone metastases","volume":"119","author":"Thio","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4103\/1450-1147.174711","article-title":"Can Neutrophil\/Lymphocyte Ratio be a Predictor for Bone Metastases of Solid Tumors?","volume":"15","author":"Caliskan","year":"2016","journal-title":"World J. Nucl. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fcell.2020.00507","article-title":"Osteoclast Signal Transduction During Bone Metastasis Formation","volume":"8","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Hofbauer, L.C., Bozec, A., Rauner, M., Jakob, F., Perner, S., and Pantel, K. (2021). Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol., 1\u201318.","DOI":"10.1038\/s41571-021-00499-9"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1152\/physrev.00012.2019","article-title":"Bone metastasis: Mechanisms, therapies, and biomarkers","volume":"101","author":"Coleman","year":"2021","journal-title":"Physiol. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00520-008-0487-0","article-title":"Metastatic bone pain: Treatment options with an emphasis on bisphosphonates","volume":"16","author":"Strasser","year":"2008","journal-title":"Support. Care Cancer"},{"key":"ref_157","first-page":"CD013020","article-title":"Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: A network meta-analysis","volume":"12","author":"Jakob","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S0305-7372(10)70013-X","article-title":"New molecular targets in bone metastases","volume":"36","author":"Santini","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: Mode of Action and Pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"100317","DOI":"10.1016\/j.jbo.2020.100317","article-title":"Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions","volume":"25","author":"George","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector \u03b3\u03b4 T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.bjc.6605814","article-title":"Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma","volume":"103","author":"Veltman","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-008-0482-9","article-title":"Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages","volume":"57","author":"Tsagozis","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_164","first-page":"1165","article-title":"The effect of zoledronic acid on the function and differentiation of myeloid cells","volume":"91","author":"Wolf","year":"2006","journal-title":"Haematologica"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00262-017-2011-1","article-title":"Zoledronic acid renders human M1 and M2 macrophages susceptible to V\u03b42+ \u03b3\u03b4 T cell cytotoxicity in a perforin-dependent manner","volume":"66","author":"Fowler","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"118","DOI":"10.18632\/oncotarget.9497","article-title":"Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts","volume":"8","author":"Comito","year":"2016","journal-title":"Oncotarget"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Liu, H., Wang, S.-H., Chen, S.-C., Chen, C.-Y., and Lin, T.-M. (2019). Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5379-9"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Liu, H., Wang, S.-H., Chen, S.-C., Chen, C.-Y., Lo, J.-L., and Lin, T.-M. (2016). Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid. BMC Immunol., 17.","DOI":"10.1186\/s12865-016-0183-7"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Li, Y., Du, Y., Sun, T., Xue, H., Jin, Z., and Tian, J. (2018). PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4412-8"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e1338238","DOI":"10.1080\/2162402X.2017.1338238","article-title":"Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer","volume":"6","author":"Sarhan","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/0008-5472.CAN-18-0548","article-title":"Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer","volume":"78","author":"Ubellacker","year":"2018","journal-title":"Cancer Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.canlet.2016.11.013","article-title":"Adoptive transfer of ex vivo expanded V\u03b39V\u03b42 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer","volume":"386","author":"Zysk","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting Human \u03b3\u03b4 T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res."},{"key":"ref_178","first-page":"37","article-title":"Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer","volume":"58","author":"Nagamine","year":"2009","journal-title":"Hiroshima J. Med Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00109-013-1021-5","article-title":"The metastasis-promoting roles of tumor-associated immune cells","volume":"91","author":"Smith","year":"2013","journal-title":"J. Mol. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2014A systematic review","volume":"62","author":"Kroep","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","article-title":"Roles of the RANKL\u2013RANK axis in antitumour immunity\u2014Implications for therapy","volume":"15","author":"Ahern","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","article-title":"RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment","volume":"133","author":"Verhoeven","year":"2019","journal-title":"Crit. Rev. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1200\/JCO.2013.51.3572","article-title":"Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma","volume":"34","author":"Smyth","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: Experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: A retrospective analysis at a tertiary care center","volume":"28","author":"Afzal","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e1431088","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Simatou, A., Sarantis, P., Koustas, E., Papavassiliou, A.G., and Karamouzis, M.V. (2020). The Role of the RANKL\/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207570"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/0300891619851376","article-title":"Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: When and why","volume":"105","author":"Gallicchio","year":"2019","journal-title":"Tumori J."},{"key":"ref_189","unstructured":"(2021, April 13). ASCO GU 2021: Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-Resistant Prostate Cancer. Available online: https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2021\/prostate-cancer\/127937-asco-gu-2021-randomized-phase-ii-study-evaluating-the-addition-of-pembrolizumab-to-radium-223-in-metastatic-castration-resistant-prostate-cancer.html."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/j.clgc.2017.10.010","article-title":"Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer","volume":"16","author":"Kim","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-20-4476","article-title":"Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer","volume":"27","author":"Marshall","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euo.2019.02.007","article-title":"Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group","volume":"3","author":"Carles","year":"2020","journal-title":"Eur. Urol. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"K\u00e4hk\u00f6nen, T.E., Halleen, J.M., and Bernoulli, J. (2021). Limited data from clinical trials assessing immunotherapy effects on bone metastases. Cancer Res., in press.","DOI":"10.1158\/1538-7445.AM2021-2870"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","article-title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"21","author":"Schmid","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","article-title":"Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series","volume":"6","author":"Moseley","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdx643","article-title":"Nivolumab-associated bone marrow necrosis","volume":"29","author":"Hilal","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Heidegger, I., Necchi, A., Pircher, A., Tsaur, I., Marra, G., Kasivisvanathan, V., Kretschmer, A., Mathieu, R., Ceci, F., and Bergh, R.C.V.D. (2020). A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?. Eur. Urol. Oncol.","DOI":"10.1016\/j.euo.2020.10.010"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1529\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:17:45Z","timestamp":1760163465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/6\/1529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":198,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cells10061529"],"URL":"https:\/\/doi.org\/10.3390\/cells10061529","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]}}}